Skip to main content
. 2020 Feb 26;3(2):e200107. doi: 10.1001/jamanetworkopen.2020.0107

Figure 2. Relative Risk (Hazard Ratios [HRs], Unadjusted and Adjusted) for Study Outcomes in Patients With Newly Diagnosed Atrial Fibrillation Treated With Oral Anticoagulants (OAC) Plus Antiplatelet Drugs (AP) or OAC Alone (Reference) Over 12 Months (Intent-to-Treat Analyses).

Figure 2.

Hazard ratios were adjusted for 40 covariates as shown in eTable 1 in the Supplement. AP indicates antiplatelet drugs; and OAC, oral anticoagulants. ACS indicates acute coronary syndromes; MI, myocardial infarction; NMCR, nonmajor, clinically relevant; and SE, systemic embolism.